SlideShare a Scribd company logo
CORONARY ARTERY DISEASE AMONG ASYMPTOMATIC DIABETIC AND NONDIABETIC PATIENTS  UNDERGOING CORONARY CT ANGIOGRAPHY   Zeina AR, Blinder J, Rosenschein U,  Zaid G ,   Barmeir E _______________________________________________________________________________ Zeina et al, Coronary Artery Disease 2008, 19:37–41
[object Object],[object Object],[object Object],_______________________________________________________________________________ ,[object Object],[object Object],[object Object],Zeina et al, Coronary Artery Disease 2008, 19:37–41 Introduction
[object Object],[object Object],[object Object],[object Object],_______________________________________________________________________________ Zeina et al, Coronary Artery Disease 2008, 19:37–41 Introduction
The aim of this study was to determine the prevalence and severity of CAD and the plaque composition in asymptomatic diabetic patients undergoing coronary CT angiography (CCTA)   _______________________________________________________________________________ Purpose Zeina et al, Coronary Artery Disease 2008, 19:37–41
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Materials and Methods _______________________________________________________________________________ Zeina et al, Coronary Artery Disease 2008, 19:37–41
Table 1. Baseline characteristics of diabetic and non-diabetic patients. _______________________________________________________________________________ Zeina et al, Coronary Artery Disease 2008, 19:37–41 0.96 101 (35) 15 (36) Smoking, n (%) 0.34 152 (53) 19 (45) Hyperlipidemia, n (%) 0.17 138 (48) 25 (59) Hypertension, n (%) 0.19 126 (44) 14 (33) Family history, n (%) 0.17  213 (74) 38 (90) Male gender, n (%) 0.10 56 ± 9 58 ± 8 Age (years ± SD) (N= 286) (N= 42)  P value Non-diabetic patients Diabetic patients
[object Object],[object Object],[object Object],[object Object],[object Object],_______________________________________________________________________________ Materials and Methods Zeina et al, Coronary Artery Disease 2008, 19:37–41
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],_______________________________________________________________________________ Results Zeina et al, Coronary Artery Disease 2008, 19:37–41
Table 2. CCTA characteristics of the study population and comparison between diabetic and non-diabetic patients. * P  value < 0.05 is considered significant. CCTA= coronary CT angiography _______________________________________________________________________________ Results Zeina et al, Coronary Artery Disease 2008, 19:37–41 0.1 1 (0.3%) 1 (2%) Three-vessel disease 0.3 2 (0.7%) 1 (2%) Two-vessel disease < 0.0001 16 (5.6%) 10 (24%) One-vessel disease  < 0.0001 2.8 5.5  Segments with plaques/patient 0.07 141 (49%) 27 (64%) Non-obstructive CAD < 0.0001 19 (6.6%) 12 (29%) Obstructive CAD  0.006 211 (74%)  39 (93%) Coronary plaques < 0.0001  79.9 ± 16 370 ± 96  Total Agatston score (n= 286) (n= 42) P  value *   Non-diabetic patients Diabetic patients
54-year-old asymptomatic diabetic patient  MIP 3D-VR CCTA Zeina et al, Coronary Artery Disease 2008, 19:37–41
Discussion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],_______________________________________________________________________________ Zeina et al, Coronary Artery Disease 2008, 19:37–41
[object Object],[object Object],[object Object],_______________________________________________________________________________ Conclusion ,[object Object],[object Object],[object Object],Zeina et al, Coronary Artery Disease 2008, 19:37–41

More Related Content

What's hot

Base Primary Prevention Decision Model
Base Primary Prevention Decision ModelBase Primary Prevention Decision Model
Base Primary Prevention Decision Model
CTSI at UCSF
 
Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?
Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?
Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?
Nuffield Trust
 
Dores et al
Dores et alDores et al
Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,
Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,
Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,
Apollo Hospitals Group and ATNF
 
Ije Okafor_Poster
Ije Okafor_PosterIje Okafor_Poster
Ije Okafor_Poster
Ije Okafor
 
Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08
Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08
Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08
Leonard Davis Institute of Health Economics
 
Purple and white modern advertising presentation
Purple and white modern advertising presentationPurple and white modern advertising presentation
Purple and white modern advertising presentation
AnjuPremy
 
Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...
Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...
Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...
Stefania Dumitrescu
 
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Central Adiposity and Mortality after First-Ever Acute Ischemic StrokeCentral Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Erwin Chiquete, MD, PhD
 
Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....
Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....
Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....
Leonard Davis Institute of Health Economics
 
How Much Does A Hospital Day Cost?
How Much Does A Hospital Day Cost?How Much Does A Hospital Day Cost?
How Much Does A Hospital Day Cost?
clearflow
 
12471_2015_Article_733
12471_2015_Article_73312471_2015_Article_733
12471_2015_Article_733
Brian Vendel
 
Risk factors for adverse coutcomes
Risk factors for adverse coutcomesRisk factors for adverse coutcomes
Risk factors for adverse coutcomes
drucsamal
 
Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...
Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...
Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...
Mutiple Sclerosis
 
The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...
The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...
The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...
asclepiuspdfs
 
Seattle heart failure model
Seattle heart failure modelSeattle heart failure model
Seattle heart failure model
drucsamal
 
HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...
HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...
HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...
Ahjo Communications Oy
 
Differences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesDifferences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomes
drucsamal
 
Ischemia Trial
Ischemia TrialIschemia Trial
Ischemia Trial
Muhammad Sanaan
 
Stopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trialStopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trial
https://aiimsbhubaneswar.nic.in/
 

What's hot (20)

Base Primary Prevention Decision Model
Base Primary Prevention Decision ModelBase Primary Prevention Decision Model
Base Primary Prevention Decision Model
 
Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?
Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?
Thierry Chassaulet: Predictive risk modelling: Does technique or time matter?
 
Dores et al
Dores et alDores et al
Dores et al
 
Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,
Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,
Measuring long term effect of Telecare on Chronic Diseases by Masatugu Tsuji,
 
Ije Okafor_Poster
Ije Okafor_PosterIje Okafor_Poster
Ije Okafor_Poster
 
Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08
Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08
Outcomes of Carotid Stent Systems Versus Endarterectomy 4.29.08
 
Purple and white modern advertising presentation
Purple and white modern advertising presentationPurple and white modern advertising presentation
Purple and white modern advertising presentation
 
Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...
Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...
Aspirin as Prevention Therapy for Cardiovascular Events in patients with Diab...
 
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Central Adiposity and Mortality after First-Ever Acute Ischemic StrokeCentral Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
 
Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....
Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....
Critical Illness Outcomes in General Versus Specialty Intensive Care Units 5....
 
How Much Does A Hospital Day Cost?
How Much Does A Hospital Day Cost?How Much Does A Hospital Day Cost?
How Much Does A Hospital Day Cost?
 
12471_2015_Article_733
12471_2015_Article_73312471_2015_Article_733
12471_2015_Article_733
 
Risk factors for adverse coutcomes
Risk factors for adverse coutcomesRisk factors for adverse coutcomes
Risk factors for adverse coutcomes
 
Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...
Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...
Novel Method for Automated Analysis of Retinal Images: Results in Subjects wi...
 
The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...
The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...
The Effect of Demographic Data and Hemoglobin A 1c on Treatment Outcomes in P...
 
Seattle heart failure model
Seattle heart failure modelSeattle heart failure model
Seattle heart failure model
 
HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...
HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...
HEC 2014 / James Peake: The Quality Journey of the U.S. Department of Veteran...
 
Differences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesDifferences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomes
 
Ischemia Trial
Ischemia TrialIschemia Trial
Ischemia Trial
 
Stopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trialStopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trial
 

Viewers also liked

204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
SHAPE Society
 
048 adventitial fat presentation
048 adventitial fat presentation048 adventitial fat presentation
048 adventitial fat presentation
SHAPE Society
 
225 animal models of heart attack part 2
225 animal models of heart attack part 2225 animal models of heart attack part 2
225 animal models of heart attack part 2
SHAPE Society
 
120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosis120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosis
SHAPE Society
 
213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosis213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosis
SHAPE Society
 
108 cetp expression
108 cetp expression108 cetp expression
108 cetp expression
SHAPE Society
 
185 towards the future cath lab
185 towards the future cath lab185 towards the future cath lab
185 towards the future cath lab
SHAPE Society
 
125 ct based characterization
125 ct based characterization125 ct based characterization
125 ct based characterization
SHAPE Society
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosis
SHAPE Society
 
No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...
SHAPE Society
 
117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteries
SHAPE Society
 
134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging
SHAPE Society
 
089 intravascular magnetic resonance imaging
089 intravascular magnetic resonance imaging089 intravascular magnetic resonance imaging
089 intravascular magnetic resonance imaging
SHAPE Society
 
257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice
SHAPE Society
 
144 physics of mri
144 physics of mri144 physics of mri
144 physics of mri
SHAPE Society
 
253 endothelial dysfunction
253 endothelial dysfunction253 endothelial dysfunction
253 endothelial dysfunction
SHAPE Society
 
3rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 33rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 3
SHAPE Society
 
230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crp
SHAPE Society
 
219 coronary autoregulation in vivo
219 coronary autoregulation in vivo219 coronary autoregulation in vivo
219 coronary autoregulation in vivo
SHAPE Society
 
249 the most cost effective therapy
249 the most cost effective therapy249 the most cost effective therapy
249 the most cost effective therapy
SHAPE Society
 

Viewers also liked (20)

204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
 
048 adventitial fat presentation
048 adventitial fat presentation048 adventitial fat presentation
048 adventitial fat presentation
 
225 animal models of heart attack part 2
225 animal models of heart attack part 2225 animal models of heart attack part 2
225 animal models of heart attack part 2
 
120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosis120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosis
 
213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosis213 oral apo ai mimetic peptide for reduction of atherosclerosis
213 oral apo ai mimetic peptide for reduction of atherosclerosis
 
108 cetp expression
108 cetp expression108 cetp expression
108 cetp expression
 
185 towards the future cath lab
185 towards the future cath lab185 towards the future cath lab
185 towards the future cath lab
 
125 ct based characterization
125 ct based characterization125 ct based characterization
125 ct based characterization
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosis
 
No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...
 
117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteries
 
134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging
 
089 intravascular magnetic resonance imaging
089 intravascular magnetic resonance imaging089 intravascular magnetic resonance imaging
089 intravascular magnetic resonance imaging
 
257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice257 inhibition of atherosclerosis in mice
257 inhibition of atherosclerosis in mice
 
144 physics of mri
144 physics of mri144 physics of mri
144 physics of mri
 
253 endothelial dysfunction
253 endothelial dysfunction253 endothelial dysfunction
253 endothelial dysfunction
 
3rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 33rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 3
 
230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crp
 
219 coronary autoregulation in vivo
219 coronary autoregulation in vivo219 coronary autoregulation in vivo
219 coronary autoregulation in vivo
 
249 the most cost effective therapy
249 the most cost effective therapy249 the most cost effective therapy
249 the most cost effective therapy
 

Similar to Coronary artery disease among asymptomatic diabetic and non-diabetic patients undergoing coronary CT angiography

Ueda 2016 dm &amp; cad-amr el hadidy
Ueda 2016 dm &amp; cad-amr el hadidyUeda 2016 dm &amp; cad-amr el hadidy
Ueda 2016 dm &amp; cad-amr el hadidy
ueda2015
 
Screening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetesScreening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetes
Shyam Jadhav
 
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Premier Publishers
 
Racial Differences in Access to New Technology 4.29.08
Racial Differences in Access to New Technology 4.29.08Racial Differences in Access to New Technology 4.29.08
Racial Differences in Access to New Technology 4.29.08
Leonard Davis Institute of Health Economics
 
Diabetic kidney disease 2021
Diabetic kidney disease 2021 Diabetic kidney disease 2021
Diabetic kidney disease 2021
Christos Argyropoulos
 
Trends in diabetes-related health indicators in Aboriginal communities in Nor...
Trends in diabetes-related health indicators in Aboriginal communities in Nor...Trends in diabetes-related health indicators in Aboriginal communities in Nor...
Trends in diabetes-related health indicators in Aboriginal communities in Nor...
Kelli Buckreus
 
Predictors of persistence with antihypertensive therapy: results from the NHANES
Predictors of persistence with antihypertensive therapy: results from the NHANESPredictors of persistence with antihypertensive therapy: results from the NHANES
Predictors of persistence with antihypertensive therapy: results from the NHANES
SHAPE Society
 
Stable angina
Stable anginaStable angina
Objetivos en diabetes: de la "evidencia" al sentido común
Objetivos en diabetes: de la "evidencia" al sentido común Objetivos en diabetes: de la "evidencia" al sentido común
Objetivos en diabetes: de la "evidencia" al sentido común
Rafael Bravo Toledo
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
MedicineAndHealthUSA
 
Diabetes Care
Diabetes CareDiabetes Care
Diabetes Care
Andrea D. Peagler
 
Cardiovascular.pptx slide for detection cancer
Cardiovascular.pptx slide for detection cancerCardiovascular.pptx slide for detection cancer
Cardiovascular.pptx slide for detection cancer
JafarHussain48
 
BP Targets-where are we now.pptx
BP Targets-where are we now.pptxBP Targets-where are we now.pptx
BP Targets-where are we now.pptx
ssuser8f64fe2
 
clopidogril and ACS
clopidogril and ACSclopidogril and ACS
clopidogril and ACS
Mahmoud Yossof
 
Hyvet Slide Set
Hyvet Slide SetHyvet Slide Set
Hyvet Slide Set
hospital
 
A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR COMPLICATIONS IN TYPE 2 DI...
A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR  COMPLICATIONS IN TYPE 2 DI...A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR  COMPLICATIONS IN TYPE 2 DI...
A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR COMPLICATIONS IN TYPE 2 DI...
IJSIT Editor
 
Ndei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes EpidemiologyNdei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes Epidemiology
david7s
 
Sympo.grandes.etudes.algerie.2020.version.04.ppt
Sympo.grandes.etudes.algerie.2020.version.04.pptSympo.grandes.etudes.algerie.2020.version.04.ppt
Sympo.grandes.etudes.algerie.2020.version.04.ppt
BassemAouiche
 
The Science Diabetes Control
The Science Diabetes ControlThe Science Diabetes Control
The Science Diabetes Control
MedicineAndDermatology
 
Stable ischemic heart disease how is it different from acs..
Stable ischemic heart disease how is it different from acs..Stable ischemic heart disease how is it different from acs..
Stable ischemic heart disease how is it different from acs..
cardiositeindia
 

Similar to Coronary artery disease among asymptomatic diabetic and non-diabetic patients undergoing coronary CT angiography (20)

Ueda 2016 dm &amp; cad-amr el hadidy
Ueda 2016 dm &amp; cad-amr el hadidyUeda 2016 dm &amp; cad-amr el hadidy
Ueda 2016 dm &amp; cad-amr el hadidy
 
Screening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetesScreening for asymptomatic cad in diabetes
Screening for asymptomatic cad in diabetes
 
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
 
Racial Differences in Access to New Technology 4.29.08
Racial Differences in Access to New Technology 4.29.08Racial Differences in Access to New Technology 4.29.08
Racial Differences in Access to New Technology 4.29.08
 
Diabetic kidney disease 2021
Diabetic kidney disease 2021 Diabetic kidney disease 2021
Diabetic kidney disease 2021
 
Trends in diabetes-related health indicators in Aboriginal communities in Nor...
Trends in diabetes-related health indicators in Aboriginal communities in Nor...Trends in diabetes-related health indicators in Aboriginal communities in Nor...
Trends in diabetes-related health indicators in Aboriginal communities in Nor...
 
Predictors of persistence with antihypertensive therapy: results from the NHANES
Predictors of persistence with antihypertensive therapy: results from the NHANESPredictors of persistence with antihypertensive therapy: results from the NHANES
Predictors of persistence with antihypertensive therapy: results from the NHANES
 
Stable angina
Stable anginaStable angina
Stable angina
 
Objetivos en diabetes: de la "evidencia" al sentido común
Objetivos en diabetes: de la "evidencia" al sentido común Objetivos en diabetes: de la "evidencia" al sentido común
Objetivos en diabetes: de la "evidencia" al sentido común
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
 
Diabetes Care
Diabetes CareDiabetes Care
Diabetes Care
 
Cardiovascular.pptx slide for detection cancer
Cardiovascular.pptx slide for detection cancerCardiovascular.pptx slide for detection cancer
Cardiovascular.pptx slide for detection cancer
 
BP Targets-where are we now.pptx
BP Targets-where are we now.pptxBP Targets-where are we now.pptx
BP Targets-where are we now.pptx
 
clopidogril and ACS
clopidogril and ACSclopidogril and ACS
clopidogril and ACS
 
Hyvet Slide Set
Hyvet Slide SetHyvet Slide Set
Hyvet Slide Set
 
A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR COMPLICATIONS IN TYPE 2 DI...
A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR  COMPLICATIONS IN TYPE 2 DI...A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR  COMPLICATIONS IN TYPE 2 DI...
A STUDY ON PREVALENCE OF MICRO AND MACRO VASCULAR COMPLICATIONS IN TYPE 2 DI...
 
Ndei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes EpidemiologyNdei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes Epidemiology
 
Sympo.grandes.etudes.algerie.2020.version.04.ppt
Sympo.grandes.etudes.algerie.2020.version.04.pptSympo.grandes.etudes.algerie.2020.version.04.ppt
Sympo.grandes.etudes.algerie.2020.version.04.ppt
 
The Science Diabetes Control
The Science Diabetes ControlThe Science Diabetes Control
The Science Diabetes Control
 
Stable ischemic heart disease how is it different from acs..
Stable ischemic heart disease how is it different from acs..Stable ischemic heart disease how is it different from acs..
Stable ischemic heart disease how is it different from acs..
 

More from SHAPE Society

Barth imt
Barth imtBarth imt
Barth imt
SHAPE Society
 
Braunwald
BraunwaldBraunwald
Braunwald
SHAPE Society
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
SHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
SHAPE Society
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
SHAPE Society
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
SHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
SHAPE Society
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
SHAPE Society
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
SHAPE Society
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
SHAPE Society
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
SHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
SHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
SHAPE Society
 
A20 gene
A20 geneA20 gene
A20 gene
SHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
SHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
SHAPE Society
 
103100
103100103100

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 

Recently uploaded

Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
dazzjoker
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
IMG_20240615_091110.pdf dpboss guessing
IMG_20240615_091110.pdf dpboss  guessingIMG_20240615_091110.pdf dpboss  guessing
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
IPLTech Electric
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
essorprof62
 
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
concepsionchomo153
 
Pro Tips for Effortless Contract Management
Pro Tips for Effortless Contract ManagementPro Tips for Effortless Contract Management
Pro Tips for Effortless Contract Management
Eternity Paralegal Services
 
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fixKalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
satta Matta matka 143 Kalyan chart jodi 6366249026
 
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
Niswey
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
obriengroupinc04
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
CIOWomenMagazine
 
CULR Spring 2024 Journal.pdf testing for duke
CULR Spring 2024 Journal.pdf testing for dukeCULR Spring 2024 Journal.pdf testing for duke
CULR Spring 2024 Journal.pdf testing for duke
ZevinAttisha
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
thesiliconleaders
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
Harwinder Singh
 
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
taqyea
 
AI Transformation Playbook: Thinking AI-First for Your Business
AI Transformation Playbook: Thinking AI-First for Your BusinessAI Transformation Playbook: Thinking AI-First for Your Business
AI Transformation Playbook: Thinking AI-First for Your Business
Arijit Dutta
 
GKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt PresentationGKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt Presentation
GraceKohler1
 
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
Ksquare Energy Pvt. Ltd.
 

Recently uploaded (20)

Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdfRegistered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
IMG_20240615_091110.pdf dpboss guessing
IMG_20240615_091110.pdf dpboss  guessingIMG_20240615_091110.pdf dpboss  guessing
IMG_20240615_091110.pdf dpboss guessing
 
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
DPBOSS NET SPBOSS SATTA MATKA RESULT KALYAN MATKA GUESSING FREE KALYAN FIX JO...
 
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【​网址​🎉ac22.net🎉​】
 
Pro Tips for Effortless Contract Management
Pro Tips for Effortless Contract ManagementPro Tips for Effortless Contract Management
Pro Tips for Effortless Contract Management
 
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fixKalyan chart 6366249026 India satta Matta Matka 143 jodi fix
Kalyan chart 6366249026 India satta Matta Matka 143 jodi fix
 
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
Unlocking WhatsApp Marketing with HubSpot: Integrating Messaging into Your Ma...
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
 
CULR Spring 2024 Journal.pdf testing for duke
CULR Spring 2024 Journal.pdf testing for dukeCULR Spring 2024 Journal.pdf testing for duke
CULR Spring 2024 Journal.pdf testing for duke
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
 
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
 
AI Transformation Playbook: Thinking AI-First for Your Business
AI Transformation Playbook: Thinking AI-First for Your BusinessAI Transformation Playbook: Thinking AI-First for Your Business
AI Transformation Playbook: Thinking AI-First for Your Business
 
GKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt PresentationGKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt Presentation
 
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
 

Coronary artery disease among asymptomatic diabetic and non-diabetic patients undergoing coronary CT angiography

  • 1. CORONARY ARTERY DISEASE AMONG ASYMPTOMATIC DIABETIC AND NONDIABETIC PATIENTS UNDERGOING CORONARY CT ANGIOGRAPHY Zeina AR, Blinder J, Rosenschein U, Zaid G , Barmeir E _______________________________________________________________________________ Zeina et al, Coronary Artery Disease 2008, 19:37–41
  • 2.
  • 3.
  • 4. The aim of this study was to determine the prevalence and severity of CAD and the plaque composition in asymptomatic diabetic patients undergoing coronary CT angiography (CCTA) _______________________________________________________________________________ Purpose Zeina et al, Coronary Artery Disease 2008, 19:37–41
  • 5.
  • 6. Table 1. Baseline characteristics of diabetic and non-diabetic patients. _______________________________________________________________________________ Zeina et al, Coronary Artery Disease 2008, 19:37–41 0.96 101 (35) 15 (36) Smoking, n (%) 0.34 152 (53) 19 (45) Hyperlipidemia, n (%) 0.17 138 (48) 25 (59) Hypertension, n (%) 0.19 126 (44) 14 (33) Family history, n (%) 0.17 213 (74) 38 (90) Male gender, n (%) 0.10 56 ± 9 58 ± 8 Age (years ± SD) (N= 286) (N= 42) P value Non-diabetic patients Diabetic patients
  • 7.
  • 8.
  • 9. Table 2. CCTA characteristics of the study population and comparison between diabetic and non-diabetic patients. * P value < 0.05 is considered significant. CCTA= coronary CT angiography _______________________________________________________________________________ Results Zeina et al, Coronary Artery Disease 2008, 19:37–41 0.1 1 (0.3%) 1 (2%) Three-vessel disease 0.3 2 (0.7%) 1 (2%) Two-vessel disease < 0.0001 16 (5.6%) 10 (24%) One-vessel disease < 0.0001 2.8 5.5 Segments with plaques/patient 0.07 141 (49%) 27 (64%) Non-obstructive CAD < 0.0001 19 (6.6%) 12 (29%) Obstructive CAD 0.006 211 (74%) 39 (93%) Coronary plaques < 0.0001 79.9 ± 16 370 ± 96 Total Agatston score (n= 286) (n= 42) P value * Non-diabetic patients Diabetic patients
  • 10. 54-year-old asymptomatic diabetic patient MIP 3D-VR CCTA Zeina et al, Coronary Artery Disease 2008, 19:37–41
  • 11.
  • 12.